Ecteinascidin

Ecteinascidin

File:Ecteinascidin743.gif
Identifiers
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}

WikiDoc Resources for Ecteinascidin
Articles
Most recent articles on Ecteinascidin Most cited articles on Ecteinascidin Review articles on Ecteinascidin Articles on Ecteinascidin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ecteinascidin Images of Ecteinascidin Photos of Ecteinascidin Podcasts & MP3s on Ecteinascidin Videos on Ecteinascidin
Evidence Based Medicine
Cochrane Collaboration on Ecteinascidin Bandolier on Ecteinascidin TRIP on Ecteinascidin
Clinical Trials
Ongoing Trials on Ecteinascidin at Clinical Trials.gov Trial results on Ecteinascidin Clinical Trials on Ecteinascidin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ecteinascidin NICE Guidance on Ecteinascidin NHS PRODIGY Guidance FDA on Ecteinascidin CDC on Ecteinascidin
Books
Books on Ecteinascidin
News
Ecteinascidin in the news Be alerted to news on Ecteinascidin News trends on Ecteinascidin
Commentary
Blogs on Ecteinascidin
Definitions
Definitions of Ecteinascidin
Patient Resources / Community
Patient resources on Ecteinascidin Discussion groups on Ecteinascidin Patient Handouts on Ecteinascidin Directions to Hospitals Treating Ecteinascidin Risk calculators and risk factors for Ecteinascidin
Healthcare Provider Resources
Symptoms of Ecteinascidin Causes & Risk Factors for Ecteinascidin Diagnostic studies for Ecteinascidin Treatment of Ecteinascidin
Continuing Medical Education (CME)
CME Programs on Ecteinascidin
International
Ecteinascidin en Espanol Ecteinascidin en Francais
Business
Ecteinascidin in the Marketplace Patents on Ecteinascidin
Experimental / Informatics
List of terms related to Ecteinascidin

Overview

Ecteinascidin 743 is a potent anti-tumor drug. First isolated from aqueous ethanol extract of tunicates in 1969, the complex molecule was found to have impressive cytocytic activities in the pico- to nanomolar range. It is composed of 3 tetrahydroquinoline moieties, 8 rings including one 10-membered heteocyclic ring containing a cystine residue, and 7 chiral centers. This structure was not determined until 1984, and was first totally synthesized by Elias James Corey in 1996.

The biological mechanism of action is believed to involve the production of superoxide near the DNA strand, resulting in DNA backbone cleavage and cell apoptosis. The actual mechanism is not yet known, but is believed to proceed from reduction of molecular oxygen into superoxide via an unusual auto-redox reaction on a hydroxyquinone moiety of the compound following. There is also some speculation the compound becomes 'activated' into its reactive oxazolidine form.

Biosynthesis is also beleieved to involve the dimerization of two tyrosine residues to form the pentacyclic core of the molecule. The total synthesis by E.J. Corey used this proposed biosynthesis in their attempt at the compounds synthetic creation. Their synthesis utilized such reactions as the Mannich reaction, Pictet-Spengler reaction, the Curtius rearrangement, and the use of chiral Rhodium-based diphosphine complex, in order to conver Z isomers into "S" enantiomers with ~100% yield. A separate synthetic process also involved the Ugi reaction to assist in the formation of the pentacyclic core. This reaction was unprecidented for using such a one pot multi-component reaction in the synthesis of such a complex molecule.